Evidence map›Paper›PMID 42381981›Full record

ArticleJournal of clinical & translational endocrinology2026

Change in circulating irisin level and its association with lipid metabolism after exenatide treatment in patients with type 2 diabetes mellitus.

Yuting Gao, Xiaoyu Hong, Kun Yang, Yunyi Le, Rui Wei, Jin Yang, Tianpei Hong, Qing Tian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical & translational endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuting GaoDepartment of Endocrinology and Metabolism, Peking University Third Hospital, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100191, China.
Xiaoyu HongDepartment of Endocrinology and Metabolism, Peking University Third Hospital, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100191, China.
Kun YangDepartment of Endocrinology and Metabolism, Peking University Third Hospital, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100191, China.
Yunyi LeDepartment of Endocrinology and Metabolism, Peking University Third Hospital, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100191, China.
Rui WeiDepartment of Endocrinology and Metabolism, Peking University Third Hospital, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100191, China.
Jin YangDepartment of Endocrinology and Metabolism, Peking University Third Hospital, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100191, China.
Tianpei HongDepartment of Endocrinology and Metabolism, Peking University Third Hospital, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100191, China.
Qing TianDepartment of Endocrinology and Metabolism, Peking University Third Hospital, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Irisin is a metabolism-related myokine associated with lipid metabolism and insulin resistance. However, its changes during glucagon-like peptide-1 (GLP-1) receptor agonist therapy remain unclear. Methods: This exploratory analysis of a multicenter trial included 189 adults with T2DM inadequately controlled with metformin and/or insulin secretagogue. The participants received the GLP-1 receptor agonist exenatide as an add-on therapy for 16 weeks. Serum irisin and glycolipid metabolism were evaluated. Comparison was performed between two subgroups of the participants stratified by a median change from baseline in serum irisin level. Associations between change in irisin level and changes in metabolic parameters were assessed using Pearson or Spearman correlation analysis and multivariable linear regression analysis. Results: After the 16-week exenatide treatment, serum irisin level significantly declined from baseline (3.22 ± 0.53 ng/mL Conclusions: Serum irisin level declines during the exenatide treatment in patients with T2DM, and this reduction is associated with change in lipid metabolism but not glycemic control, suggesting a potential link between dynamic change of irisin and lipid metabolism during the exenatide treatment.

Indexed as

ExenatideGLP-1 receptor agonistIrisinLipid metabolismType 2 diabetes mellitus

Identifiers

PMID42381981
PMCPMC13315098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.